Chimerix Inc. (NASDAQ:CMRX)’s share price traded up 3.1% on Tuesday . The stock traded as high as $4.68 and last traded at $4.64, with a volume of 116,372 shares trading hands. The stock had previously closed at $4.50.

Several equities analysts have weighed in on the stock. FBR & Co restated a “hold” rating on shares of Chimerix in a report on Tuesday, May 10th. Zacks Investment Research upgraded shares of Chimerix from a “hold” rating to a “buy” rating and set a $5.25 target price for the company in a report on Wednesday, May 11th. Piper Jaffray Cos. set a $12.00 target price on shares of Chimerix and gave the company a “buy” rating in a report on Thursday, August 18th. Finally, JPMorgan Chase & Co. restated a “hold” rating and set a $7.00 target price on shares of Chimerix in a report on Tuesday, August 9th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $15.72.

The stock’s 50 day moving average price is $4.24 and its 200-day moving average price is $4.83. The company’s market capitalization is $211.66 million.

Chimerix (NASDAQ:CMRX) last issued its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.51) by $0.12. The business earned $1.80 million during the quarter, compared to analyst estimates of $1.98 million. Analysts anticipate that Chimerix Inc. will post ($1.78) EPS for the current year.

In other news, Director Ernest Mario acquired 50,000 shares of Chimerix stock in a transaction on Friday, June 24th. The stock was bought at an average cost of $3.70 per share, with a total value of $185,000.00. Following the completion of the purchase, the director now owns 381,440 shares of the company’s stock, valued at $1,411,328. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO M Michelle Berrey acquired 13,188 shares of Chimerix stock in a transaction on Friday, June 24th. The shares were purchased at an average cost of $3.69 per share, with a total value of $48,663.72. Following the completion of the purchase, the chief executive officer now directly owns 258,821 shares of the company’s stock, valued at approximately $955,049.49. The disclosure for this purchase can be found here.

A hedge fund recently raised its stake in Chimerix stock. Trexquant Investment LP boosted its position in shares of Chimerix Inc. (NASDAQ:CMRX) by 453.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 131,184 shares of the biopharmaceutical company’s stock after buying an additional 107,484 shares during the period. Trexquant Investment LP owned approximately 0.28% of Chimerix worth $1,174,000 as of its most recent SEC filing.

Chimerix, Inc (Chimerix) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antivirals. The Company, based on its lipid conjugate technology, has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.